← Leaderboards
Eli Gilboa
Duke University
$17,521,988
Attributed
$18,058,451
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,688,076 · 14
By mechanism
R01$13,060,809 · 9
DP1$3,829,825 · 1
P01$755,848 · 2
R37$623,139 · 1
R21$418,455 · 1
Top collaborators
- Sundaram Ramakrishnan3 shared
Most similar at Duke University
Same institution · by research overlap
- John H Sampson$43,413,436
- David Reardon$8,732,934
- Andrew J Armstrong$4,232,419
- Guido Ferrari$29,050,364
- Annick Desjardins$3,762,272
Others in their field
Top investigators on “Oligonucleotides”
- Monte Westerfield · University Of Oregon$78,765,009
- David Heimbrook · Leidos Biomedical Research, Inc.$73,743,088
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Randall J Bateman · Washington University$63,044,576
- Larry Arthur$39,727,172
- Ronald Wayne Davis · Stanford University$38,345,338
Research focus
OligonucleotidesImmunityIn VitroImmuneCellsAptamerBaseT-LymphocyteImmune ResponseTumorPreventModalitySmall Interfering RnaMalignant NeoplasmsClinical TrialsMelanomaAntigensLigandsPharmaceutical PreparationsCost EffectiveCancer PatientImmunogenicityLaboratory MouseNeoplasm /Cancer Immunotherapy
Grant awards (59)
Vaccination against antigens induced by TAP downregulation in concurrent and future tumors$351,131
R01 · FY2025 · CA · contact PI
Vaccination against antigens induced by TAP downregulation in concurrent and future tumors$333,575
R01 · FY2024 · CA · contact PI
Vaccination against antigens induced by TAP downregulation in concurrent and future tumors$344,109
R01 · FY2023 · CA · contact PI
Vaccination against antigens induced by TAP downregulation in concurrent and future tumors$344,109
R01 · FY2022 · CA · contact PI
Role of HSP70 in Pancreatic Diseases$321,544
R01 · FY2022 · CA
Vaccination against antigens induced by TAP downregulation in concurrent and future tumors$351,131
R01 · FY2021 · CA · contact PI
Role of HSP70 in Pancreatic Diseases$328,106
R01 · FY2021 · CA
Role of HSP70 in Pancreatic Diseases$423,276
R01 · FY2020 · CA
Reversing HIV T cell dysfunction by aptamer targeting of therapeutic siRNAs$767,500
DP1 · FY2019 · DA · contact PI
Reversing HIV T cell dysfunction by aptamer targeting of therapeutic siRNAs$767,500
DP1 · FY2018 · DA · contact PI
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells$318,513
R01 · FY2018 · CA · contact PI
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells$100,813
R01 · FY2018 · CA · contact PI
Reversing HIV T cell dysfunction by aptamer targeting of therapeutic siRNAs$767,500
DP1 · FY2017 · DA · contact PI
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells$318,513
R01 · FY2017 · CA · contact PI
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells$100,813
R01 · FY2017 · CA · contact PI
Reversing HIV T cell dysfunction by aptamer targeting of therapeutic siRNAs$759,825
DP1 · FY2016 · DA · contact PI
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells$318,513
R01 · FY2016 · CA · contact PI
Enhancing Immunological Memory Using Aptamer targeted siRNA Delivery to T Cells$100,813
R01 · FY2016 · CA · contact PI
Reversing HIV T cell dysfunction by aptamer targeting of therapeutic siRNAs$767,500
DP1 · FY2015 · DA · contact PI
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells$318,513
R01 · FY2015 · CA · contact PI
Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay$317,475
R01 · FY2015 · CA · contact PI
Enhancing Immunological Memory Using Aptamertargeted siRNA Delivery to T Cells$318,513
R01 · FY2014 · CA · contact PI
Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay$307,951
R01 · FY2014 · CA · contact PI
Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay$298,427
R01 · FY2013 · CA · contact PI
Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay$317,475
R01 · FY2012 · CA · contact PI
Expressing New Tumor Antigens by Inhibition of Nonsense Mediated mRNA Decay$317,475
R01 · FY2011 · CA · contact PI
Oligonucleotide aptamer ligands to reverse T cell anergy in HIV-infected patients$227,205
R21 · FY2011 · AI · contact PI
Oligonucleotide aptamer ligands to reverse T cell anergy in HIV-infected patients$191,250
R21 · FY2010 · AI · contact PI
Development of Oligonucleotide-based CTLA-4 Inhibitors$297,398
R01 · FY2008 · CA · contact PI
Development of Oligonucleotide-based CTLA-4 Inhibitors$297,236
R01 · FY2007 · CA · contact PI
Cancer Immunotherapy Targeting Endothelial Antigens$286,084
R01 · FY2007 · CA · contact PI
Cancer Immunotherapy w/In-Situ Maturated Dendritic cells$331,610
R01 · FY2006 · CA · contact PI
Cancer Immunotherapy Targeting Endothelial Antigens$195,963
R01 · FY2006 · CA · contact PI
Development of Oligonucleotide-based CTLA-4 Inhibitors$167,750
R01 · FY2006 · CA · contact PI
Development of Oligonucleotide-based CTLA-4 Inhibitors$136,769
R01 · FY2006 · CA · contact PI
Cancer Immunotherapy Targeting Endothelial Antigens$100,832
R01 · FY2006 · CA · contact PI
Cancer Immunotherapy w/In-Situ Maturated Dendritic cells$2,987
R01 · FY2006 · CA · contact PI
Cancer Immunotherapy w/In-Situ Maturated Dendritic cells$342,650
R01 · FY2005 · CA
Development of Oligonucleotide-based CTLA-4 Inhibitors$315,700
R01 · FY2005 · CA
Cancer Immunotherapy Targeting Endothelial Antigens$308,385
R01 · FY2005 · CA
CANCER VACCINATION AGAINST TELOMERASE$242,550
R01 · FY2005 · CA
Cancer Immunotherapy w/In-Situ Maturated Dendritic cells$326,037
R01 · FY2004 · CA
Development of Oligonucleotide-based CTLA-4 Inhibitors$315,700
R01 · FY2004 · CA
Cancer Immunotherapy Targeting Endothelial Antigens$308,385
R01 · FY2004 · CA
CANCER VACCINATION AGAINST TELOMERASE$242,550
R01 · FY2004 · CA
TUMOR RNA TRANSFECTED DENDRITIC CELL VACCINES$242,550
R01 · FY2004 · CA
Cancer Immunotherapy w/In-Situ Maturated Dendritic cells$342,650
R01 · FY2003 · CA
Cancer Immunotherapy Targeting Endothelial Antigens$308,385
R01 · FY2003 · CA
CANCER VACCINATION AGAINST TELOMERASE$242,550
R01 · FY2003 · CA
TUMOR RNA TRANSFECTED DENDRITIC CELL VACCINES$242,550
R01 · FY2003 · CA
TUMOR RNA TRANSFECTED DENDRITIC CELL VACCINES$242,550
R01 · FY2002 · CA
CANCER VACCINATION AGAINST TELOMERASE$242,550
R01 · FY2002 · CA
INTRACELLULAR IMMUNIZATION VIA TAR DECOYS IN PBL$316,174
R37 · FY2001 · AI
CANCER VACCINATION AGAINST TELOMERASE$242,550
R01 · FY2001 · CA
TUMOR RNA TRANSFECTED DENDRITIC CELL VACCINES$242,550
R01 · FY2001 · CA
HIV GENE THERAPY WITH RNA INHIBITORS$629,625
P01 · FY2000 · AI
INTRACELLULAR IMMUNIZATION VIA TAR DECOYS IN PBL$306,965
R37 · FY2000 · AI
TUMOR RNA TRANSFECTED DENDRITIC CELL VACCINES$242,550
R01 · FY2000 · CA
CORE--RETROVIRAL VECTOR CONSTRUCTION FACILITY$126,223
P01 · FY2000 · AI